UNITO-001-A Phase II Study in HRR/PDL1 Positive MPM/NSCLC
Status:
Recruiting
Trial end date:
2024-01-15
Target enrollment:
Participant gender:
Summary
This is a single arm, prospective, interventional, multicenter phase 2 study of the
combination of niraparib and dostarlimab in patients with advanced non-small cell lung cancer
(NSCLC) and/or malignant pleural mesothelioma (MPM), and positive for PD-L1 expression (TPS ≥
1%) and germline or somatic mutations in the DNA homologous recombination repair (HRR) genes.